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Editorial
IntRoductIon
Multiple sclerosis (MS) is a disease that is characterized by loss 
of myelin (demyelinization).[1] In MS, demyelinization usually 
affects white matter in the brain, but sometimes it extends into 
the gray matter. When myelin is damaged, nerve fiber conduction 
is faulty or absent, and nerve cell death may occur. Impaired 
bodily functions or altered sensations associated with those 
demyelinated nerve fibers give rise to the symptoms of MS, which 
range from numbness to paralysis and blindness. People with MS 
experience attacks of symptoms that may last days, months, or 
longer. For many patients, the disease is progressive and leads 
to disablement, although some cases enter long, perhaps even 
permanent, remission. The cause of MS is unknown.[1]
General epidemiological factors
MS is not contagious or directly inherited; epidemiologists 
have identified factors in the distribution of MS around the 
world that may eventually help determine what causes the 
disease.[1]
MS is thought to affect >2.3 million people worldwide. 
The factors associated with MS are gender, genetics, age, 
geography, and ethnic background.[1]
Age factors
Most people are diagnosed between the ages of 20 and 
50 years, although MS can occur in young children and 
significantly older adults.[1]
Gender factors
MS is at least two to three times more common in women 
than in men, suggesting that hormones. Recent MS studies 
have suggested that the female to male ratio may be as high 
as 4 to 1.[1]
Ethnic factors
MS is more common in Caucasians of northern European 
ancestry.[1] Rates of occurrence may differ significantly 
among groups living in the same geographic area regardless 
of distance from the equator.[1]
Geographic factors
In general, MS is more common in areas farthest from the 
equator.[1] The MS prevalence rates may differ signiificantly 
among groups living in the same geographic area regardless 
of distance from the equator. Some environmental trigger in 
genetically susceptible individuals.
Diagnosis of multiple sclerosis
No single test can diagnose MS. The medical history, 
neurologic examination, and laboratory tests help physicians 
rule out other diseases and confirm the MS diagnosis.[1] 
“Improvement in neuroimaging techniques such as positron 
emission tomography or magnetic resonance imaging (MRI) 
carries a promise for better diagnosis and prognostic 
predictions.”[1]
In order to make a diagnosis of MS, the physician must find 
evidence of damage in at least two separate areas of the central 
nervous system (CNS), which includes the brain, spinal cord, 
and optic nerves and (a) find evidence that the damage occurred 
at different points in time and (b) rule out all other possible 
diagnoses.[1]
MS is now being more frequently diagnosed in India due to 
two important factors, namely (a) increase in the number of 
practicing neurologists and (b) availability of MRI.[2] The cases 
of MS in India display the same clinical features and outcome 
as those cases seen in the Western countries.[2]
MoleculaR MaRkeRs
In recent years, newly emerging highly specific molecular 
markers called “microRNAs” had appeared in the research 
literature, which are found both in the peripheral blood and the 
cerebrospinal fluid in the realm of such neurological diseases as 
amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease, and MS.[3‑10]
What makes these microRNA (miRNA) markers so potentially 
useful in clinical neurology is that they are seen very early 
on long before the appearance of symptoms and other 
confirmatory conventional indicators of pathology.[3‑10]
What aRe MIcRoRnas
“A miRNA is a small noncoding RNA molecule (containing 
about 22 nucleotides) found in plants, animals, and 
some viruses, which functions in RNA silencing and 
posttranscriptional regulation of gene expression.[4] While 
the majority of miRNAs are located within the cell, some 
miRNAs, commonly known as circulating miRNAs or 
extracellular miRNAs, have also been found in extracellular 
environment, including various biological fluids and cell 
culture media.”[4]
“Extracellular miRNAs in serum, plasma, saliva, and urine 
have recently been shown to be associated with various 
pathological conditions including cancer.”
In a recent article that appeared in the journal “Neurology,” 
Reed et al. noted that miRNAs were prodromal biomarkers 
for Huntington’s disease.[8]
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microRNA molecular markers found in multiple sclerosis 
patients
A minimally invasive blood‑based specimen type is what is 
needed in the quest for early detection of a potential MS scenario.
Vesicles known as exosomes contain RNA, DNA, and 
proteins.[11] These structures can cross the blood–brain 
barrier.[11] These exosomes are secreted from a broad variety 
of cell types which include the cells of the CNS.[11]
Ebrahimkhani et al. hypothesized that serum exosomal 
miRNAs could therefore provide the means for a useful 
blood‑based assay for MS disease detection and monitoring.[11] 
These investigators therefore utilized exosome‑associated 
miRNAs derived from 25 serum samples from MS patients.[11]
Ebrahimkhani et al. found nine miRNAs (miR‑15b‑5p, 
miR‑23a‑3p, miR‑223‑3p, miR‑374a‑5p, miR‑30b‑5p, 
miR‑433‑3p, miR‑485‑3p, miR‑342‑3p, and miR‑432‑5p)[11] This 
important discovery allowed these investigators to distinguish 
relapsing‑remitting disease from progressive disease. Eight out 
of the nine miRNAs were validated in an independent group 
(n = 11) of progressive MS cases.[11]
The investigation of Ebrahimkhani et al. was the first 
demonstration that miRNAs associated with circulating 
exosomes are informative biomarkers not only in the diagnosis 
of MS, but in predicting disease subtype with a high degree of 
accuracy.[11]
conclusIon
The recent advancements in the field of miRNA research now 
have provided clinical neurologists with technologies that 
will make possible both a diagnosis of MS and also enable a 
prediction of disease subtype.
The detection of MS using miRNA molecular markers is now 
at hand to be utilized in the realm of clinical neurology!!
The ability to also utilize minimally invasive blood‑based 
specimen types for applications involving early detection of 
a potential MS scenario has provided additional rational for 
using miRNA markers in the practice of clinical neurology!!
Thus, the time has now arrived for clinical neurologists to 
intensely apply these miRNAs on a routine basis for early 
detection of MS.
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